Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPACT-PM
NCT07655440Phase 4Not yet recruiting
- Sponsor
- Stanford University
- Start
- Jul 2026
- Primary completion
- Jul 2031
01
Overview
A Phase 4 trial of galcanezumab, erenumab, eptinezumab, atogepant in tinnitus, sponsored by Stanford University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
galcanezumaberenumabeptinezumabatogepant
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT07655440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655440.